Reviews for Primary Care - Fall 2007 - (Page 28) Chronic Constipation and Functional Bowel Disorders continued References 1. Drossman DA. Diagnosing and treating patients with refractory functional gastrointestinal disorders. Ann Intern Med. 1995;123:688-697. Drossman DA, sr ed. Rome III: The Functional Gastrointestinal Disorders. 3rd ed. McLean, VA: Degnon Associates, Inc; 2006. Camilleri M. Functional gastrointestinal disorders: novel insights and treatments. Medscape General Medicine Web site. http://www. medscape.com/viewarticle/407938. Published November 1, 1999. Accessed August 1, 2007. Thompson WG. The road to Rome. Gastroenterology. 2006;130:1552-1556. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377-1390. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920-924. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(suppl 2):II43-II47. Rao SSC. Constipation: evaluation and treatment. Gastroenterol Clin North Am. 2003;32:659-683. Locke GR III, Pemberton JH, Phillips SF. American Gastroenterological Association medical position statement: guidelines on constipation. Gastroenterology. 2000;119:1761-1778. Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003;349:1360-1368. Mertz H, Naliboff B, Mayer E. Physiology of refractory chronic constipation. Am J Gastroenterol. 1999;94:609-615. Foxx-Orenstein A. IBS—review and what’s new. MedGenMed. 2006;8:20. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132:397-414. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology. 1998;115:370-380. Kim D-Y, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol. 2000;95:2698-2709. Crowell MD. The role of serotonin in the pathophysiology of irritable bowel syndrome. Am J Manag Care. 2001;7(8 suppl):S252-S260. Lacy BE, Yu S. Tegaserod: a new 5-HT4 agonist. J Clin Gastroenterol. 2002;34:27-33. Streutker CJ, Huizinga JD, Driman DK, Riddell RH. Interstitial cells of Cajal in health and disease. Part II: ICC and gastrointestinal stromal tumours. Histopathology. 2007;50:190-202. He C-L, Burgart L, Wang L, et al. Decreased interstitial cell of Cajal volume in patients with slow-transit constipation. Gastroenterology. 2000; 118:14-21. Prather CM. Subtypes of constipation: sorting out the confusion. Rev Gastroenterol Disord. 2004;4(suppl 2):S11-S16. 22. 2. 23. 3. 24. 25. 26. 4. 5. 6. 27. 7. 28. 8. 29. 9. 10. 30. 11. 12. 31. 32. 13. 14. 33. 15. 34. 16. 35. 17. 18. 19. 36. 37. 20. 21. 38. Harrell LE, Chang EB. Intestinal water and electrolyte transport. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease e-dition: Pathophysiology, Diagnosis, Management. 8th ed. Philadelphia, PA: Saunders; 2005: Chapter 96. Rubinstein S, Moss R, Lewiston N. Constipation and meconium ileus equivalent in patients with cystic fibrosis. Pediatrics. 1986;78:473-479. Wald A. Chronic constipation: advances in management. Neurogastroenterol Motil. 2007;19:4-10. Physicians’ Desk Reference. 61st ed. Montvale, NJ: Thomson PDR; 2007. Drugs, supplements, and herbal information. Medline Plus Web site. http://www.nlm.nih.gov/ medlineplus/druginformation.html. Updated June 5, 2007. Accessed August 9, 2007. Ambizas EM, Ginzburg R. Lubiprostone: a chloride channel activator for treatment of chronic constipation. Ann Pharmacother. 2007;41:957-964. Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol. 2004;287: C1173-C1183. Lacy BE, Campbell Levy L. Lubiprostone: a chloride channel activator. J Clin Gastroenterol. 2007;41:345-351. Cash BD, Chang L, Sabesin SM, Vitat P. Update on the management of adults with chronic idiopathic constipation. J Fam Pract. 2007;56 (suppl):S1-S8. Brandt LJ, Prather CM, Quigley EM, et al. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(suppl 1):S5-S21. Remes-Troche JM, Rao SSC. Diagnostic testing in patients with chronic constipation. Curr Gastroenterol Rep. 2006;8:416-424. Agrawal S, Bhupinderjit A, Bhutani MS, et al. Committee of Minority Affairs and Cultural Diversity, American College of Gastroenterology. Colorectal cancer in African Americans. Am J Gastroenterol. 2005;100:515-523. Rao SSC, Ozturk R, Laine L. Clinical utility of diagnostic tests for constipation in adults: a systematic review. Am J Gastroenterol. 2005;100: 1605-1615. Minguez M, Herreros B, Sanchiz V, et al. Predictive value of the balloon expulsion test for excluding the diagnosis of pelvic floor dyssynergia in constipation. Gastroenterology. 2004;126: 57-62. Thornton MJ, Lubowski DZ. Assessment of the constipated patient: an overview. In: Wexner SD, Zbar P, Pescatori M, eds. Complex Anorectal Disorders: Investigation and Management. London: Springer; 2005:412-428. MiraLAX®, number one doctor-prescribed laxative, now available over the counter. ScheringPlough Web site. http://www.schering-plough. com/schering_plough/news/release.jsp?releaseID= 978827. Published March 28, 2007. Accessed August 3, 2007. FDA public health advisory: tegaserod maleate (marketed as Zelnorm). US Food and Drug 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. Administration Web site. http://www.fda.gov/ cder/drug/advisory/tegaserod.htm. Published March 30, 2007. Accessed August 9, 2007. FDA permits restricted use of Zelnorm for qualifying patients. US Food and Drug Administration Web site. http://www.fda.gov/bbs/topics/NEWS/ 2007/NEW01673.html. Published July 27, 2007. Accessed August 9, 2007. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97(11 suppl):S7-S26. Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol. 2005; 100:232-242. Ramkumar D, Rao SSC. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol. 2005;100:936-971. Physicians’ Desk Reference. 59th ed. Montvale, NJ: Thomson PDR; 2005. DiPalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebocontrolled trial of polyethylene glycol laxative for treatment of chronic constipation. Am J Gastroenterol. 2007;102:1436-1441. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25:599-608. Lembo A. Irritable bowel syndrome medications side effects survey. J Clin Gastroenterol. 2004; 38:776-781. Guidelines for the evaluation of probiotics in food. World Health Organization Web site. http://www. who.int/foodsafety/publications/fs_management/ probiotics2/en/index.html. Accessed August 9, 2007. Fernández-Bañares F. Nutritional care of the patient with constipation. Best Pract Res Clin Gastroenterol. 2006;20:575-587. Bouvier M, Meance S, Bouley C, et al. Effects of consumption of a milk fermented with the probiotic strain Bifidobacterium animalis DN-173 010 on colonic transit times in healthy humans. Biosci Microflora. 2001:20:43-48. Posserud I, Stotzer P-O, Björnsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56: 802-808. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412-419. Pimentel M, Chatterjee S, Chow EJ, et al. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci. 2006;51:1297-1301. Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326-333. Simren M, Stotzer P-O. Use and abuse of hydrogen breath tests. Gut. 2006;55:297-303. VOL. 1 NO. 1 2007 REVIEWS FOR PRIMARY CARE http://www.fda.gov/cder/drug/advisory/tegaserod.htm http://www.fda.gov/cder/drug/advisory/tegaserod.htm http://www.fda.gov/bbs/topics/NEWS/2007/NEW01673.html http://www.fda.gov/bbs/topics/NEWS/2007/NEW01673.html http://www.medscape.com/viewarticle/407938 http://www.medscape.com/viewarticle/407938 http://www.nlm.nih.gov/medlineplus/druginformation.html http://www.nlm.nih.gov/medlineplus/druginformation.html http://www.who.int/foodsafety/publications/fs_management/probiotics2/en/index.html http://www.who.int/foodsafety/publications/fs_management/probiotics2/en/index.html http://www.who.int/foodsafety/publications/fs_management/probiotics2/en/index.html http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=978827 http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=978827 http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=978827
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.